Merck & Co., Inc. (NYSE:MRK) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In. Following a decline in revenue in the second quarter of 2025, the company received the FDA approval for ...

FDA approves Keytruda Qlex, a subcutaneous injection version of the widely used cancer therapy Keytruda Patients can now receive treatment in as li ...

In September 2025, Merck received FDA approval for KEYTRUDA QLEX, a subcutaneous version of its flagship cancer therapy, ...

Patients taking the immunotherapy drug Keytruda (pembrolizumab) may now have the option to take it as a quick shot instead of as a slower IV infusion.

Wall Street analysts expect the subcutaneous version of Keytruda, which just launched last week, to help soften the blow when the original loses patent protection later this decade.

Sue McCarthy shares her experience overcoming stage 3B lung cancer, reflecting on the impact of her diagnosis. After ...

Keytruda Qlex is a fixed combination of pembrolizumab, a PD-1-blocking antibody, and berahyaluronidase alfa, a variant of human hyaluronidase. The addition of berahyaluronidase enhances dispersion and ...

FDA approves Merck's Keytruda Qlex injection for adults with solid tumors. Merck expects it to be available in the U.S. in September.

Though MSD's subcutaneous Keytruda is more patient-centric, analysts are sceptical of the drug’s capacity to stave off generic competition.

The FDA has approved Keytruda Qlex, a faster, under-the-skin cancer treatment offering convenience and flexibility. Here's what we know.

Positive opinion granted for SC administration of KEYTRUDA for all adult indications approved in the European Union for KEYTRUDA Positive opinion also granted for KEYTRUDA as part of a perioperative ...